Temperature effect on the sensitivity of ELISA, PA and WB to detect anti-HIV-1 antibody and infectivity of HIV-1

Chinese Medical Journal (Taipei)

Volumn 59, Issue 6, 1997, Pages 325-333

  Wang, Gong Ren ^a,b,c   Yang, Jyh Yuan ^b   Lin, Tsuey Li ^b   Chen, Hour Young ^b   Horng, Chi Byi ^b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b Executive Yuan   (Taiwan)

^c NONE   (Taiwan)

Author keywords

Acquired immunodeficiency syndrome; Enzyme linked immunosorbent assay; Human immunodeficiency virus; Particle agglutination; Western blotting

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

AGGLUTINATION TEST; ARTICLE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PATHOGENICITY; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TEMPERATURE; WESTERN BLOTTING;

AGGLUTINATION TESTS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TEMPERATURE;

EID: 28244450334     PISSN: 05781337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S. Isolation of a T-lymphotropic retrovirus from a patient at risk to acquired immune deficiency syndrome (AIDS). Science 1983;220:867-71.
2. Richman DD. HIV therapeutics. Science 1996;272:1886-8.
3. Bloom BB. A perspective on AIDS vaccine. Science 1996;272:1888-90.
4. Centers for Disease Control. Problems created by heat-inactivation of serum specimens before HIV-1 antibody testing. MMWR 1989;38:407-13.
5. Martin LS, McDougal JS, Loskoski SL. Disinfection and inactivation of the human T lymphotropic virus type III/lymphadenopathy-associated virus. J Infect Dis 1985;152:400-3.
6. Popovic M, Sarngadharan MG, Read E, Gallo RC. Isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1989;224:497-500.
7. Smith SD, Shatsky M, Cohen PS, Warnke R, Link MP, Glader BE. Monoclonal antibody and enzymatic profiles of human malignant T lymphoid cells and derived cell lines. Cancer Res 1984;44:5657-60.
8. Sarngadharan MG, Popovic M, Bruch L, Schupbach J, Gallo R. Antibodies reactive with human T lymphotropic retrovirus (HTLV-III) in the serum of patients with AIDS. Science 1984;224:506-8.
9. Shirazian D, Herzlich BC, Mokhtarian. F, Grob D. Detection of HIV antibody and antigen (p24) in residual blood on needle and glass. Infect Cont Hosp Ep1990;11:180-4.
10. Evans RP, Shahson DC, Mortimer PP. Clinical evaluation of Abbott and Wellcome enzyme-linked immunosorbent assays for detection of serum antibodies to human immunodeficiency virus (HIV). J Clin Pathol 1987;40:552-5.
11. McBride JH, Howantiz PJ, Rodgerson DO, Miles J, Peter JB. Influence of specimen treatment on nonreactive HTLV-III sera. AIDS Res Hum Retrov 1987;3:333-40.
12. Centers for Disease Control. Interpretation and use of the western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR 1989;262:3395-7.
13. World Health Organization. Acquired immunodeficiency syndrome (AIDS) proposed WHO criteria for interpreting results from western blot assays for HIV-1, HIV-2, HTLV-1/HTLV-II. Wkly Epidem Rec 1990;65:281-8.
14. Petersen LR, Satten GA, Dodd R, Busch M, Kleinman S, Grindon A, Lenes B. Duration of time from onset of human immunodeficiency virus type one infectiousness to development of detectable antibody. Transfusion 1994;34:283-9.
15. Busch MP, Lee LLL, Satten GA, Henrard DR, Farzadegan H, Nelson KE, Dodd RY, Petersen LR. Time course of detection of viral and serologic markers preceeding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995;35:91-7.
16. Lackritz EM, Satten GA, Aberle-Grasse J, Dodd RY, Raimardi VP, Janssen RS, Lewis WF, Notari EP, Petersen LR. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995;333:1721-5.
17. Alter HJ, Epstein JS, Swenson SG, VanRaden MJ, Ward JW, Kaslow RA, Menitove JE, Klein HG, Sandler SG, Sayers MH, Chernoff AI, Hewlett IK. Prevalence of human immunodeficiency virus type 1 p24 antigens in US blood donors-an assessment of the efficacy of testing in donor screening. N Engl J Med 1990;323:1312-7.
18. Mundee Y, Kamtorn N, Chaiyaphruk, Nantachit N, Ness PM, Nelson KE. Infectious disease markers in blood donors in northern Thailand. Transfusion 1995;35:264-7.
19. Centers for Disease Control. U.S. public health service guidelines for testing and counseling blood and plasma donors for human immunodeficiency virus type 1 antigen. MMWR 1996;45(RR-2):1-9.
20. Stromberg RR, Kuypers FA, Sawyer L, Friedman L, Cole M, Tran K, Hanson CV. Loss of red blood cell viability associated with limited thermal inactivation of extracellular HIV-1. Vox Sang 1994;67: 260-6.
21. Centers for Disease Control. Recommendations for preventive of HIV transmission in health-care settings. MMWR 1987;36(suppl 2):3-18.
22. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR 1988;37:377-88.